SK281258B6 - (s)-alfa-2-pyridínetánamín, farmaceutická kompozícia s jeho obsahom a jeho použitie - Google Patents

(s)-alfa-2-pyridínetánamín, farmaceutická kompozícia s jeho obsahom a jeho použitie Download PDF

Info

Publication number
SK281258B6
SK281258B6 SK1177-94A SK117794A SK281258B6 SK 281258 B6 SK281258 B6 SK 281258B6 SK 117794 A SK117794 A SK 117794A SK 281258 B6 SK281258 B6 SK 281258B6
Authority
SK
Slovakia
Prior art keywords
phenyl
pyridineethanamine
pharmaceutically acceptable
dose
compound
Prior art date
Application number
SK1177-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK117794A3 (en
Inventor
Ronald Conrad Griffith
Robert John Murray
Michael Balestra
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of SK117794A3 publication Critical patent/SK117794A3/sk
Publication of SK281258B6 publication Critical patent/SK281258B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SK1177-94A 1992-04-03 1993-04-01 (s)-alfa-2-pyridínetánamín, farmaceutická kompozícia s jeho obsahom a jeho použitie SK281258B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
SK117794A3 SK117794A3 (en) 1995-05-10
SK281258B6 true SK281258B6 (sk) 2001-01-18

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1177-94A SK281258B6 (sk) 1992-04-03 1993-04-01 (s)-alfa-2-pyridínetánamín, farmaceutická kompozícia s jeho obsahom a jeho použitie

Country Status (29)

Country Link
EP (1) EP0633879B1 (ru)
JP (2) JP3120810B2 (ru)
KR (1) KR100259567B1 (ru)
CN (1) CN1044367C (ru)
AT (1) ATE163925T1 (ru)
AU (2) AU3897693A (ru)
CA (1) CA2133427C (ru)
CZ (1) CZ288519B6 (ru)
DE (1) DE69317411T2 (ru)
DK (1) DK0633879T3 (ru)
DZ (1) DZ1677A1 (ru)
ES (1) ES2115055T3 (ru)
FI (1) FI105025B (ru)
HK (1) HK1009331A1 (ru)
HU (1) HU211529A9 (ru)
IL (1) IL105276A (ru)
MA (1) MA22866A1 (ru)
MX (1) MX9301935A (ru)
MY (1) MY110149A (ru)
NO (1) NO302170B1 (ru)
NZ (1) NZ251384A (ru)
PL (1) PL180014B1 (ru)
RU (1) RU2128650C1 (ru)
SG (1) SG47948A1 (ru)
SK (1) SK281258B6 (ru)
TW (1) TW282455B (ru)
UA (1) UA29437C2 (ru)
WO (1) WO1993020052A1 (ru)
ZA (1) ZA932415B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
EP0648489A1 (en) * 1988-08-12 1995-04-19 Fisons Corporation Arylalkylamides having neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
SG171928A1 (en) 2008-12-24 2011-07-28 Astrazeneca Ab Ethanamine compounds and their use for treating depression
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Gabr−a2診断
PT3066091T (pt) 2013-11-05 2019-07-11 Astrazeneca Ab Pro-farmacos de antagonista de nmda
US20230190719A1 (en) * 2020-06-23 2023-06-22 Biohaven Therapeutics Ltd. Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648489A1 (en) * 1988-08-12 1995-04-19 Fisons Corporation Arylalkylamides having neuroprotective properties

Also Published As

Publication number Publication date
EP0633879B1 (en) 1998-03-11
TW282455B (ru) 1996-08-01
AU3897693A (en) 1993-11-08
DK0633879T3 (da) 1998-09-28
SG47948A1 (en) 1998-04-17
EP0633879A1 (en) 1995-01-18
CN1081669A (zh) 1994-02-09
NO302170B1 (no) 1998-02-02
NZ251384A (en) 1996-10-28
SK117794A3 (en) 1995-05-10
MA22866A1 (fr) 1993-12-31
CZ240994A3 (en) 1995-12-13
CA2133427C (en) 2003-06-10
MX9301935A (es) 1994-08-31
ZA932415B (en) 1993-10-22
DE69317411T2 (de) 1998-07-30
CN1044367C (zh) 1999-07-28
NO943645L (no) 1994-11-16
IL105276A0 (en) 1993-08-18
IL105276A (en) 1997-06-10
HU211529A9 (en) 1995-11-28
NO943645D0 (no) 1994-09-30
PL180014B1 (pl) 2000-11-30
CA2133427A1 (en) 1993-10-14
FI944546A (fi) 1994-09-30
FI944546A0 (fi) 1994-09-30
AU7545696A (en) 1997-02-13
RU2128650C1 (ru) 1999-04-10
JP2000319259A (ja) 2000-11-21
CZ288519B6 (cs) 2001-07-11
DE69317411D1 (de) 1998-04-16
AU705419B2 (en) 1999-05-20
JPH07505385A (ja) 1995-06-15
WO1993020052A1 (en) 1993-10-14
HK1009331A1 (en) 1999-05-28
UA29437C2 (ru) 2000-11-15
DZ1677A1 (fr) 2002-02-17
MY110149A (en) 1998-02-28
KR100259567B1 (ko) 2000-07-01
JP3120810B2 (ja) 2000-12-25
FI105025B (fi) 2000-05-31
ES2115055T3 (es) 1998-06-16
ATE163925T1 (de) 1998-03-15
RU94042465A (ru) 1996-07-20

Similar Documents

Publication Publication Date Title
DE60209504T2 (de) Carbocyclische hydrazino-hemmer von kupferhaltigen aminoxidasen
DE69813896T2 (de) Alpha-aminoamidderivate die als analgetische mittel nützlich sind
SK281258B6 (sk) (s)-alfa-2-pyridínetánamín, farmaceutická kompozícia s jeho obsahom a jeho použitie
DE69230498T2 (de) 2-Pyrazinylethylamin-Derivate und ihre Verwendung als Arzneimittel.
JP3023987B2 (ja) (S)−α−フェニル−2−ピリジンエタンアミン(S)−マレートおよび医薬としてのその使用
US5455259A (en) Compounds for the treatment of neurodegenerative disorders
AU639722B2 (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
JP3023988B2 (ja) (S)−α−フェニル−2−ピリジンエタンアミンベンゾエートおよび医薬としてのその使用
EP1596852B1 (de) Arzneimittel enthaltend substituierte 2-heteroaryl-aminoessigsäure-verbindungen
DE10306202A1 (de) Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20130401